N-甲基(噻唑-5-基)甲胺 | 933751-05-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基(噻唑-5-基)甲胺
• 中文别名: 甲基噻唑-5基甲胺
• 英文名称: N-(thiazol-5-ylmethyl)methylamine
• 英文别名: Methyl-thiazol-5-ylmethyl-amine；N-methyl-1-(1,3-thiazol-5-yl)methanamine
• CAS: 933751-05-4
• 化学式: C₅H₈N₂S
• mdl: MFCD02853608
• 分子量: 128.198
• InChiKey: BVDWIWZWZZLCGR-UHFFFAOYSA-N

物化性质

• 沸点：
  199.0±15.0 °C(Predicted)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  N-甲基(噻唑-5-基)甲胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 thiazol-5-ylmethyl N-[(1R,4R)-1-benzyl-4-[[(2S)-3-methyl-2-[[methyl(thiazol-5-ylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]carbamate
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

  摘要：

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.057
• 作为产物：
  描述：

  甲胺 在 甲基磺酰氯 、 三乙胺 作用下， 以 乙腈 、 水 为溶剂， 反应 12.33h， 生成 N-甲基(噻唑-5-基)甲胺
  参考文献：
  名称：

  WO2008/10921

  摘要：

  公开号：

文献信息

• Discovery of Novel Thieno[2,3-d]pyrimidin-4-yl Hydrazone-Based Cyclin-Dependent Kinase 4 Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationships
  作者：Takao Horiuchi、Yasuyuki Takeda、Noriyasu Haginoya、Masaki Miyazaki、Motoko Nagata、Mayumi Kitagawa、Kouichi Akahane、Kouichi Uoto

  DOI：10.1248/cpb.59.991

  日期：——

  The design, synthesis, and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitors are described. In continuing our program aim to search for potent CDK4 inhibitors, the introduction of a thiazole group at the hydrazone part has led to marked enhancement of chemical stability. Furthermore, by focusing on the optimization at the C-4' position

  描述，设计和合成新型噻吩并[2,3-d]嘧啶-4-基类似物作为细胞周期蛋白依赖性激酶4（CDK4）抑制剂。在继续我们的计划以寻找有效的CDK4抑制剂的过程中，在part部分引入噻唑基团导致化学稳定性显着提高。此外，通过集中于噻唑环的C-4'位置和噻吩并[2,3-d]嘧啶部分的C-6位置的优化，已确定化合物35在HCT116异种移植模型中有效细胞。在本文中，我们对合成化合物的效价，选择性和结构活性关系进行了讨论。
• 噻唑烷基吡啶胺类化合物及其制备方法与应 用
  申请人：湖南化工研究院有限公司

  公开号：CN105777741B

  公开（公告）日：2019-02-01

  本发明公开了式(I)所示的噻唑烷基吡啶胺类化合物及其制备方法与应用。式中R、R’、Z、R1、R2具有说明书中所给定义。本发明式(I)化合物具有杀菌、杀螨或除草生物活性，尤其是对病原菌如油菜菌核病菌和黄瓜灰霉病菌等具有很高的活性。
• INHIBITORS OF CYTOCHROME P450
  申请人：Gilead Sciences, Inc.

  公开号：EP2231628B1

  公开（公告）日：2015-10-28
• WO2008/10921
  申请人：——

  公开号：——

  公开（公告）日：——
• Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)
  作者：Lianhong Xu、Hongtao Liu、Allen Hong、Randy Vivian、Bernard P. Murray、Christian Callebaut、You-Chul Choi、Melody S. Lee、Jennifer Chau、Luong K. Tsai、Kirsten M. Stray、Robert G. Strickley、Jianhong Wang、Leah Tong、Swami Swaminathan、Gerry R. Rhodes、Manoj C. Desai

  DOI：10.1016/j.bmcl.2013.12.057

  日期：2014.2

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.